Form 4: Dyne Therapeutics Executive Jonathan McNeill Sells Shares to Cover Tax Obligations

Chief Business Officer Jonathan McNeill sold 1,823 shares of Dyne Therapeutics stock to cover tax obligations related to vesting restricted stock units.

Summary

• On June 11, 2024, Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, sold 1,823 shares of common stock.
• The sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) granted on December 10, 2021, and December 9, 2022.
• The shares were sold at a weighted average price of $31.34, with individual transactions ranging from $31.00 to $31.52.
• Following the transaction, McNeill still beneficially owns 134,811 shares, including 122,885 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a routine occurrence across publicly traded companies.
• Similar sales are frequently observed among executives at comparable biotech firms like Sarepta Therapeutics and BioMarin Pharmaceutical, often tied to RSU vesting events.
• The volume of shares sold is relatively small compared to the executive's overall holdings, which is typical in these situations.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders as it is a small percentage of the outstanding shares and is related to tax obligations.

Key Dates